Kalaris Therapeutics
KLRS
56 hedge funds and large institutions have $73.4M invested in Kalaris Therapeutics in 2026 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 11 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 9
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 58 → 56 (-2)
5.24% less ownership
Funds ownership: 81.03% → 75.79% (-5.2%)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
40% less capital inflows, than outflows
Capital inflows: $5.4M | Capital outflows: $9.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.33M |
| 2 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$745K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$497K |
| 4 |
Renaissance Technologies
New York
|
+$432K |
| 5 |
Verdad Advisers
Boston,
Massachusetts
|
+$417K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Paradigm Biocapital Advisors
New York
|
-$4.04M |
| 2 |
Propel Bio Management
Los Angeles,
California
|
-$1.72M |
| 3 |
KCM
Kalehua Capital Management
Dallas,
Texas
|
-$782K |
| 4 |
Simplify Asset Management
Las Vegas,
Nevada
|
-$504K |
| 5 |
Goldman Sachs
New York
|
-$491K |
KLRS Hedge Fund Activity: Q2 2026 in Review
56 of the 8,365 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q2 2026, worth a combined $73.4M — down 32% from $107M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of KLRS and 9 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 18 added.
The largest buyer was UBS Group, adding an estimated $1.33M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $4.04M sold.
- 56 institutional investors held Kalaris Therapeutics (KLRS) as of Q2 2026, down from 58 in Q1 2026.
- Funds reported $73.4M of Kalaris Therapeutics stock for Q2 2026, down 32% quarter-over-quarter.
- 9 funds opened new Kalaris Therapeutics positions in Q2 2026 and 11 closed out, a net change of -2 holders.
- The largest Kalaris Therapeutics buyer in Q2 2026 was UBS Group, an estimated $1.33M added.
- The largest Kalaris Therapeutics seller in Q2 2026 was Paradigm Biocapital Advisors, an estimated $4.04M sold.
Based on aggregated 13F filings for Q2 2026.